SHC Stock Overview
Engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Sotera Health Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.82 |
| 52 Week High | US$17.44 |
| 52 Week Low | US$10.71 |
| Beta | 2.08 |
| 11 Month Change | -17.29% |
| 3 Month Change | -16.86% |
| 1 Year Change | -7.77% |
| 33 Year Change | -40.87% |
| 5 Year Change | n/a |
| Change since IPO | -48.92% |
Recent News & Updates
Recent updates
Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable
Sep 02
Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt
Jun 25Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 30The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%
Mar 21Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models
Mar 01McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount
Feb 08Is Sotera Health (NASDAQ:SHC) A Risky Investment?
Feb 06Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump
Dec 28Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price
Dec 11An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued
Sep 10Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jun 05Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?
Feb 13Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher
Nov 24Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit
Sep 19Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?
Sep 08Shareholder Returns
| SHC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -10.4% | 2.8% | 2.2% |
| 1Y | -7.8% | 2.9% | 31.7% |
Return vs Industry: SHC underperformed the US Life Sciences industry which returned 3.1% over the past year.
Return vs Market: SHC underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| SHC volatility | |
|---|---|
| SHC Average Weekly Movement | 5.4% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SHC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SHC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3,000 | Michael Petras | soterahealth.com |
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Sotera Health Company Fundamentals Summary
| SHC fundamental statistics | |
|---|---|
| Market cap | US$3.51b |
| Earnings (TTM) | US$70.49m |
| Revenue (TTM) | US$1.12b |
51.5x
P/E Ratio3.2x
P/S RatioIs SHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHC income statement (TTM) | |
|---|---|
| Revenue | US$1.12b |
| Cost of Revenue | US$502.46m |
| Gross Profit | US$618.01m |
| Other Expenses | US$547.52m |
| Earnings | US$70.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 55.16% |
| Net Profit Margin | 6.29% |
| Debt/Equity Ratio | 473.4% |
How did SHC perform over the long term?
See historical performance and comparison